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Abstract
Background: The clinical and economic burden of type 2 diabetes mellitus on society is rising. Effective and
efficient preventive measures may stop the increasing prevalence, given that type 2 diabetes mellitus is mainly a
lifestyle-driven disease. The Feel4Diabetes-study aimed to tackle unhealthy lifestyle (unhealthy diet, lack of physical
activity, sedentary behaviour, and excess weight) of families with a child in the first grades of elementary school.
These schools were located in regions with a relatively low socio-economic status in Belgium, Bulgaria, Finland,
Greece, Hungary and Spain. Special attention was paid to families with a high risk of developing type 2 diabetes
mellitus.
Methods: The aim of this paper is to describe the detailed methodology of the intervention’s cost-effectiveness
analysis. Based on the health economic evaluation of the Toybox-study, both a decision analytic part and a Markov
model have been designed to assess the long-term (time horizon of 70 year with one-year cycles) intervention’s
value for money. Data sources used for the calculation of health state incidences, transition probabilities between
health states, health state costs, and health state utilities are listed. Intervention-related costs were collected by
questionnaires and diaries, and attributed to either all families or high risk families only.
Conclusions: The optimal use of limited resources is pivotal. The future results of the health economic evaluation
of the Feel4Diabetes-study will contribute to the efficient use of those resources.
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Background
Prevalence of Diabetes Mellitus is on the rise. While 50
years ago, the worldwide prevalence of patients with
diabetes was estimated to be approximately 30 million
[1], the latest estimates of the International Diabetes
Federation (IDF) go up to 415 million patients with
diabetes aged 20 to 79, accounting for a global health-
care burden of 673 billion US dollars. Without improved
preventive measures, the prevalence is expected to rise
exponentially with another 50% by 2040. Over 10% of
the global population will suffer from diabetes [2].
Type 2 diabetes mellitus (T2DM) is mainly a lifestyle-
driven disease [3], with sedentary behaviour, lack of phys-
ical activity, unhealthy diet, and excess weight among the
most important risk factors [4]. The Feel4Diabetes-study
aimed to tackle T2DM in elementary school children and
their parents through intensive lifestyle modifications [5].
The British National Institute for Health and Care
Excellence (NICE) guidelines recommend to focus lifestyle
interventions on populations at risk [6], such as low-to-
middle-income countries (LMICs) where 80% of all
T2DM patients live [7], and regions in high-income coun-
tries (HICs) with high unemployment rates (31% increased
risk) or low average education levels (41% increased risk)
[8]. Hence, the Feel4Diabetes-study targeted low socioeco-
nomic status (SES) communities, and special attention is
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paid to families at increased risk to develop T2DM within
those low SES communities [5]. All adults were screened
with the Finnish Diabetes Risk Score (FINDRISC) ques-
tionnaire (a short questionnaire assessing age, body mass
index (BMI), waist circumference, lifestyle, and medical
history) to differentiate high risk families (HRF) from low
risk families (LRF) [9]. Extra measures, such as counseling
sessions, were taken to mitigate the risk level in the HRF.
The intervention group was compared to a control group
in different schools. Control schools were asked to
continue with their standard curriculum, but HRF in the
control group received general advice for a healthy and
active lifestyle in a one-hour session. The total study
sample comprised of 6450 and 5743 families, of which
1273 and 957 were HRF, in the respective intervention
and control group. Participating children were on average
8.2 years old. About 90 and 78% of the maternal and pa-
ternal parent were younger than 45 years old. A detailed
description of the Feel4Diabetes-study and the participat-
ing population can be found in Manios et al. [5].
A health economic evaluation informs healthcare policy
makers on the value for money of alternative healthcare
services across disciplines and countries. This paper out-
lines the design and the data input used for the health
economic evaluation of the Feel4Diabetes-study. The
Feel4Diabetes-study had been implemented in six partici-
pating countries. Belgium and Finland represented the
HICs, Greece and Spain the high-income countries under
austerity measures, and Hungary and Bulgaria the LMICs.
Low SES regions had been determined in HICs as de-
scribed elsewhere [5]. All regions in Hungary and Bulgaria
were defined as low SES regions. Total intervention time
covered two years, starting in September 2016 [5].
Methods
Our health economic model is based on the model by
Pil et al. [10], and has been modified with respect to the
intervention’s objectives and target population’s charac-
teristics. The original model was developed to assess the
Toybox-intervention [11], the aim of which was to tackle
obesity. Pil et al. described an indirect method to
conduct a health economic evaluation of measures pre-
venting non-communicable diseases from childhood on.
Changes in energy balance-related behaviours (EBRBs)
were used as predictors for weight loss, eventually lead-
ing to a reduction in disease prevalence. However, the
main objective of the Feel4Diabetes-study was to reduce
the risk of T2DM. Since the population in the study was
young and the follow-up time only 2 years, instead of
measuring the incidence of T2DM, the risk markers of
T2DM were measured. Excess weight is one of the best
risk markers, so BMI is the main surrogate marker for
T2DM in this study, although there is no one-on-one re-
lation. Still, a modified version of the original model was
considered to be the best possible option in meeting our
study’s objective. A comprehensive justification for our
choice to select this model can be found in the discus-
sion section.
Structure of the health economic model
The health economic model consists of a decision ana-
lytic part and a Markov model. The intervention cost
will be weighed against the intervention’s health benefits
in both the children and their parents since Feel4Dia-
betes is a holistic school- and community based inter-
vention impacting the life of the whole family.
Decision analytic part
The decision analytic part of the health economic model
will run based on (i) intervention-driven relative risk re-
ductions (RRR) in overweight and obesity and/or (ii) RRR
in EBRBs, with the former option getting priority. The first
option is to classify participants on weight status (based
on BMI), resulting in three groups: normal weight (BMI <
25), overweight (BMI 25–30) and obesity (BMI > 30). The
Feel4Diabetes-study will result in different weight status
distributions between the intervention and control group.
The second option is to conduct a health economic evalu-
ation based on an RRR in eight targeted, mediating EBRBs
(Table 1), indirectly affecting the weight status distribu-
tion. This approach may be preferred over the direct BMI-
approach because it can take years before a full decrease
in bodyweight after a change in lifestyle can be observed
[21]. We were able to directly derive the relative risk (RR)
of EBRBs on obesity/overweight from studies [19, 20] or
to calculate the RR if the risk in the control group was re-
ported [12, 14, 15, 17, 18]. In the event that an RR could
not be derived, a conservative RR was estimated based on
the odds ratio (OR) and the risk in the total sample
[13, 15, 16]. In children, the literature seems to be incon-
clusive on the association between the consumption of
fruits and berries, vegetables and sweets on the one hand,
and weight status on the other hand. In adults, the litera-
ture seems to be inconclusive on the association between
the consumption of water and sweets on the one hand,
and weight status on the other hand. Hence the exclusion
of the aforementioned EBRBs from analyses (Table 1).
Markov model
T2DM incidence and mortality in young adulthood is low
to negligible [4]. Therefore, the subsequent Markov model
starts at age 30 and stops after 70 one-year cycles, enabling
us to capture long-term effects and costs (Fig. 1). Both the
intervention effect on the targeted children and their par-
ents are incorporated in the model. The adult population
is split up in six age groups (< 30, 30–34, 35–39, 40–44,
45–49, > 50). Parents who are younger than 30 and older
than 50 start in the model at the respective age of 30 and
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50. The proportion in, for instance, the age group 30–34
is distributed evenly over the years. Children’s entry in the
Markov model is less straightforward. As in Pil et al. [10],
we used the tracking study of Venn et al. [22] to extrapo-
late the child’s current weight status to his/her weight sta-
tus at adult age (the start of the Markov model).
The 11 health states are included in the health eco-
nomic model (Fig. 1): at risk, diabetes, stroke, coronary
heart disease (CHD), colorectal cancer (CRC), breast
cancer (BC), and death. A differentiation is made be-
tween the first year after diagnosis (e.g. CHD1) and
follow-up years (e.g. CHD1+) in stroke, CHD, CRC, and
BC as utility levels and costs appeared to be significantly
different. Only females can make the transition to the
health state BC. The model is a simplification of reality
since other comorbidities are not considered. The entire
cohort starts in the ‘at risk health state’, with a distribu-
tion of weight status. Transition probabilities are a func-
tion of the underlying weight status distribution, which
is different between the intervention and the control
group as a result of the intervention.
Main health economic outcome
The incremental-cost-effectiveness ratio (ICER) is the
main health economic outcome and can be expressed as
costs per Quality Adjusted Life Year (QALY) gained. A
QALY is a measurement that incorporates both the quan-
tity (the number of years lived in a certain health state)
and quality of life (a score of 0 represents death and 1 rep-
resents perfect health). The ICER is the ratio between the
difference in costs and the difference in QALYs between
the intervention cohort and the control cohort:
Table 1 EBRBs and relative risk on overweight/obesity
Children Adults
EBRBs behaviour Relative risk on
overweight/obesity
reference behaviour Relative risk on
overweight/obesity
reference
Water consumption 1.1 glass of water per day
difference
1.33 [12] inconclusive literature
Fruits and berries inconclusive literature 3.13 daily servings
difference
1.23Ɨ (overweight)1.25Ɨ
(obesity)
[13]
Vegetables inconclusive literature 3.13 daily servings
difference
1.19Ɨ (overweight)1.15Ɨ
(obesity)
[13]
Screen time > 4 h per day 2.00 [14] > 21 h per week 1.38 [15]
Sweets inconclusive literature inconclusive literature
Sugar-sweetened
beverages
> 1 sugary drink per day 1.22Ɨ [16] > 1 soft drink per
day
1.30 [17]
Daily physical activity < 60 min per day 1.35 [18] < 5 days per week
30 min
1.07Ɨ [15]
Breakfast pattern daily breakfast taking 3.03 (overweight); 2.13
(obesity)
[19] daily breakfast taking 1.19 [20]
Ɨ: conservative estimates of relative risks, derived from odds ratio and prevalence in the control group.
Fig. 1 Markov model with 11 health states
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ICER ¼ COSTintervention−COSTcontrol
QALYintervention−QALYcontrol
The model was developed with Microsoft® Excel 2016
(Microsoft Corporation, Redmond, WA, USA).
Clinical data input
Epidemiological data
Country-, gender- and age-specific weight status preva-
lence were derived from Eurostat [23]. Weight status
prevalence in all countries, except Bulgaria and Hungary,
were adjusted for SES. Since low SES regions were de-
fined differently across countries [5], we chose to adjust
for SES in a conservative way: we calculated the RR for
excess weight in the lower educated half of the popula-
tion. Table 2 shows how overweight and obesity prevail
more often in low SES groups, except in the Finnish
population [24].
Transition probabilities
 Transition probabilities from the at risk state to
disease states in the control group were derived
from European databases and international
publications [10, 25–30]. The transition probabilities
in the intervention group were adjusted for the
change in weight status as a result from the
Feel4Diabetes intervention. For instance, overweight
and obese men have respectively 125 and 450%
more risk to develop T2DM (Table 3) [31]. Missing
data were imputed by calculating the diseases’ total
incidence ratio between countries with Belgium as
reference country.
 Transition probabilities from the diabetes state to
other disease states: patients with diabetes are at
risk to develop other diseases. Compared to
healthy counterparts, the RR to develop
comorbidities ranges from 1.23 for BC to 2.19 for
CHD (Table 3) [32–34].
 Transition probabilities to the death state: country-,
gender- and age-specific all-cause mortality rates were
derived from Eurostat, the World Health
Organization and the Belgian mortality table [35–37].
These rates were multiplied with the relative mortality
risk for patients with diabetes, to obtain the mortality
risk for the health state ‘diabetes’ (Table 3) [38].
Belgian cancer mortality rates were obtained from the
Belgian Cancer Registry [39, 40]. Dutch data were
used to estimate mortality in CHD and stroke [41]
since Belgian data were not available. Missing data
were imputed by calculating the diseases’ total
mortality ratio between countries with Belgium as
reference country.
 Transition probabilities from disease state (e.g. BC) to
the follow-up disease state (e.g. BC1): the transition
probability is 100% minus the transition probability to
the death state.
Utilities
Health state-specific utility values to calculate QALYs
were derived from international literature [42–46] and
can be found in Additional file 1: Table S1. More specif-
ically, a utility decrement was calculated for each disease.
Country-specific publications were applied where pos-
sible, but we frequently had to extrapolate data from
other European countries [44, 47–59]. For instance,
since no Bulgarian data were available, Bulgarian utilities
were assumed equal to Hungarian utilities. In our model,
we differentiated between the first year after diagnosis
and the follow-up years. Patients may experience an im-
proved quality of life in the follow-up years but they risk
a relapse, which we took into account when calculating
the health state utilities [60–63].
Cost data input
All costs are converted to the euro currency value of the
year 2016 if necessary. The health economic evaluation
considers two types of costs: disease state-related costs
and intervention costs. A societal perspective is chosen
to incorporate both direct (medical) costs and indirect
costs associated with productivity loss.
Disease state costs
Direct, country-specific, annual disease costs were de-
rived from published literature [59, 64–79].
The indirect costs of T2DM, BC and CHD were calcu-
lated by multiplying the direct costs with respectively
0.91, 0.71 and 0.8 [80–82]. The indirect cost of stroke
equals the direct cost [66, 82]. The country-specific in-
direct costs of CRC were extrapolated from Finnish data.
A ratio of direct/indirect CRC costs was calculated based
on Farkkila et al., and applied on other countries [68].
The indirect cost related to death was calculated with
a friction cost period of 160 days [83]. The actual hours
worked within this time interval was multiplied with the
average productivity cost per hour [84, 85]. These costs
were only applied on participants between the age of 30
and 64, and were adjusted for the country-specific
Table 2 Relative risk to be overweight and obese in the lower
educated half of the adult population, compared with the total
adult population
Belgium Finland Greece Spain
Men Overweight 1.05 0.97 1.07 1.07
Obese 1.12 1.03 1.30 1.30
Women Overweight 1.24 1.04 1.33 1.33
Obese 1.39 0.89 1.46 1.46
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unemployment rate and for the principle of labour time
elasticity, which states that production drops 8% when
labour time drops 10% [83, 86].
To account for T2DM as a comorbidity in other dis-
ease states, 17.91, 19.80, 23.75 and 38.24% of the cost of
T2DM was added to CHD, stroke, BC and CRC, respect-
ively [87–89]. Costs in follow-up states were adjusted for
potential relapse [60–63]. Costs were stratified for age
(younger and older than 65 years) and an extra distinction
was made between costs in T2DM patients younger and
older than 55 years [90]. Missing data were imputed based
on countries’ health expenditure per capita [91, 92] with
Belgium as reference country.
Additional file 1: Table S2 shows the total costs per
disease, stratified for age and country.
Intervention costs
Intervention costs can be attributed to the school-based
component - which targets all children - or to the HRF
component. Only those costs that would also be in-
curred in a future real-life implementation of the inter-
vention were included in the evaluation. Therefore, costs
attributable to the project planning, intervention mater-
ial development or scientific evaluation were excluded.
Costs attributable to the distribution and analysis of the
EBRBs questionnaire were taken partly into account, as
it contains the FINDRISC questionnaire [9] to classify
families into LRF and HRF. Hence, it is part of the inter-
vention model: these costs were attributed to the HRF
component. Table 4 summarizes the intervention costs
related to the school-based and HRF component.
Table 3 Relative risk values used in the health economic evaluation of F4D. Overweight and obese men/women compared to
normal weight. Diabetic men/women compared to healthy counterparts
All-cause mortality CHD Stroke Diabetes BC CRC
Age < 50 50–59 60–69 70+ < 55 < 65 65+ < 65 65+ <60y 60-74y 75+ < 50 50+ < 45 45+
At Risk Men Overweight 1.20 1.20 1.19 1.18 1.35 1.35 1.25 1.20 1.15 2.25 2.15 2.13 – – 1.20 1.18
Obese 1.55 1.54 1.52 1.50 2.00 2.00 1.70 1.50 1.38 5.50 5.14 5.05 – – 1.40 1.36
At Risk Women Overweight 1.15 1.15 1.14 1.14 1.35 1.35 1.25 1.20 1.15 2.30 2.20 2.17 1.00 1.12 1.08 1.07
Obese 1.50 1.49 1.48 1.45 2.00 2.00 1.70 1.55 1.41 7.00 6.52 6.40 1.00 1.12 1.10 1.09
Diabetic Men 1.57 1.57 1.57 1.57 2.19 1.43 1.33 1.83 1.83 – – – 1.23 1.23 1.26 1.26
Diabetic Women 2.00 2.00 2.00 2.00 2.19 1.43 1.33 2.28 2.28 – – – 1.23 1.23 1.26 1.26
BC: breast cancer; CHD: coronary heart disease; CRC: colorectal cancer
Table 4 Intervention costs
School-based component High Risk Family component
Scientific Staff · Time attributed to communication with
schools, directors and teachers
· Facilitation of the intervention (information
distribution, feedback, problem-solving)
· Delivery of intervention material· Delivering
the teachers’ training session
· Transportation costs
· Time attributed to communication with
high-risk parents
· Delivering the HRF group and individual
sessions
· Transportation costs
Community Stakeholders and NGO’s · Extra time spending due to the study
· Extra incurred costs due to the study
High Risk Families · Transportation cost to the counseling sessions
· Time spending at the counseling session·
Incurred costs related to a changing lifestyle (e.g.
gym subscription, training equipment, weight scale)
Teachers · Travel time to the training session·
Transportation cost to the training session
· Time spent at the training session· Time
spent for the implementation of the
intervention before and after school time
· Incurred costs related to the implementation of
the intervention.
Other · Distribution cost and production cost of
newsletters· Other intervention costs reported by
the scientific staff (i.e. intervention material)
· Distribution, collection and analysis of the
FINDRISC questionnaire· Costs related to the
SMS intervention
· Other intervention costs reported by the
scientific staff (i.e. intervention material)
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Intervention costs related to the school-based component
The school-based component focused on changes at
school, at home and at the municipality level. First, a
questionnaire collected the costs associated with
teachers’ training (mode of transport, transportation
time, training time). In addition, teachers were asked at
the end of the first intervention year if they invested
extra time, next to their regular labour time, or spent
money due to the project. The same method was applied
to collect the costs made by collaborating community
stakeholders and non-governmental organizations. Time
and costs spent at already existing community activities
(and which are not extended due to the Feel4Diabetes-
study) were not included as these costs were not incre-
mental. Second, newsletters made families aware of
opportunities to change their lifestyle in a healthy way.
All children in a class received the newsletters, but not
all children participated in the Feel4Diabetes-study.
Therefore, we computed the accurate cost of producing
and distributing the newsletters to participants. Third,
monthly diaries assessed the time-investment of project
staff (e.g. communication with schools, training the
teachers, SMS-intervention), their transportation costs
and miscellaneous costs.
Intervention costs related to the HRF component
The HRF component extended the school-based compo-
nent by offering six group and individual counseling ses-
sions to HRF parents during the first intervention year
and a 7th session at the start of the second intervention
year. HRF were asked to report all incurred lifestyle
modification costs (e.g. gym costs, sport clothes, cooking
books) and their transportation mode to the counseling
sessions. The 7th counseling session introduced HRF to
the SMS-intervention, which ran in the second interven-
tion year [5]. A monthly questionnaire was filled in by
the Finnish firm Extensive Life Oy (developer of the
SMS-intervention) to collect all SMS-intervention-
related costs. Some countries produced invoices due to
country-specific modifications of the intervention. These
invoices were used to validate reported costs.
Missing data in HRF and in teachers were imputed
based on the average of available information in the
country of interest. Kilometer refund in the case of
transportation per car is a function of the countries’ un-
leaded 95 RON gasoline price (October 27th, 2017) and
the official Belgian work-related kilometer refund in
2016/2017.
Analysis
Results will be reported as QALYs and costs per 1000
boys or girls targeted, and stratified for the HRF-
component and the all families (LRF and HRF) compo-
nent. Effects are discounted at 1.50% and costs at 3%,
conform Belgian Health Care Knowledge Centre’s guide-
lines. As mentioned above, the intervention effect in
children has been extrapolated from childhood to the
point in adulthood that they enter the Markov model.
Thereby discounting already started in childhood, lead-
ing to very strong discounts of the long term health
effects and costs. Tornado diagrams (one-way sensitivity
analysis) will display ±30% uncertainty intervals sur-
rounding included parameters. Furthermore, second
order Monte Carlo simulation will capture parameter
uncertainty by varying parameters all together. Included
parameters in the sensitivity analyses will be annual cost
and utilities of health states, health states’ annual inci-
dence and mortality rates, effect of the intervention,
intervention cost, and RRR (in weight status or EBRBs).
Several scenario analyses (e.g. maximizing and minima-
lizing the discount rate) will be conducted to capture
uncertainty regarding modeling assumptions. Costs,
probabilities and RRR are modeled using a gamma
distribution, a beta distribution and a lognormal distri-
bution respectively [93]. Budget impact analysis will
assess the scalability of the intervention. Only the inter-
vention costs for the healthcare budget holder will be in-
cluded (e.g. HRF’s transportation costs to the sessions
will be excluded). The budget impact will be calculated
for different time horizons between 1 and 30 years, with
the intervention being implemented every three years.
Only the avoided healthcare costs in the parents will be
included as cost offsets (the long term avoided health-
care costs in children are excluded due to the extrapola-
tion of the intervention effect in childhood to benefits in
adulthood, i.e. beyond the time horizon of the budget
impact analysis). We assume the size of the target popu-
lation to be stable over time.
Results
N/A.
Discussion
The Feel4Diabetes-study consisted of a school-, commu-
nity-, and family-based intervention targeting T2DM in
low SES regions. Additional measures were taken to foster
outcomes in HRF [5]. One of the project’s objectives was
to conduct a health economic evaluation, as health policy
makers are burdened with the task to make use of the
restricted budget in an efficient way. The current paper
describes the methodology on how the long-term cost-
effectiveness of the Feel4Diabetes-study will be assessed.
A two-part health economic model, consisting of a de-
cision analytic part and a Markov model, was designed
based on the health economic model used to assess the
Toybox-study [10, 11]. Although Toybox’s main focus
was obesity while the Feel4Diabetes-study focused on
T2DM, the newly designed model suits our aims the
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best. Weight status is in our model the mediator to re-
duce T2DM because the Feel4Diabetes-study aimed to
tackle T2DM by targeting obesity and obesity-related
metabolic risk factors [5]. Given that 90% of T2DM
patients have excess weight [94], it is not surprisingly
the single best T2DM incidence predictor, with an
explanatory factor of at least 60% [95]. The same risk
factors were targeted in Toybox. In fact, some interven-
tion materials from Toybox were adapted to the specific
needs in the Feel4Diabetes-study [5, 11]. Weight status
is associated not only with diabetes but with a range of
pathologies (e.g. CRC), resulting in 11 health states in
our model. It was crucial to include these health states
to not underestimate the intervention’s effect. Differenti-
ating the diabetes health state by adding health problems
such as nephropathy and foot ulcers/amputations
[96, 97] would be appropriate if the intervention’s target
population were patients with diabetes, contrary to the ‘at
risk target population’ in the Feel4Diabetes-study. More-
over, extra assumptions would then have been made to as-
sign country-specific costs and utilities to those health
states. This would affect the model’s complexity and
transparency significantly. However, it is important to find
the right balance between specificity and complexity, i.e.
transparency. Therefore, we chose to include a general
diabetes health state as an intermediate endpoint, for
which we were able to assign age- and country-specific
costs and utilities.
Predicting the cost-effectiveness results at this point is
speculative, though published literature may set the
prospects. Li et al. [98] reviewed T2DM prevention pro-
grams focusing on combined diet and physical activity
promotion in at-risk populations. There was a wide var-
iety in delivery methods across the prevention programs:
individual-based, group-based and mixed. All but two
studies (out of 16 studies reporting ICERs) reported
ICERs under the applied willingness-to-pay threshold.
The studies in which the cost effectiveness exceeded the
acceptable threshold were both individual-based. As
described above, the Feel4Diabetes-study focused on low
SES regions and HRF received both individual and group
counseling sessions. The total intervention cost of the
included studies in Li et al.’s review [98] varied based on
whether healthcare professionals (such as physicians or
nurses) or trained laypersons (such as lay health educa-
tors, or trained community health workers) delivered the
intervention, with the latter being less costly. It was
decided that in the Feel4Diabetes-study, in order to im-
prove the potential cost-effectiveness of the study, the
researchers (trained laypersons) would be trained to
deliver the individual- and group-based sessions. More-
over, Li et al. [98] found that programs more cost-
effective longer-term follow-up studies. Therefore, an
SMS-intervention is designed to take place in the second
year of the intervention to foster the outcomes obtained
by the more intensive first-year intervention. A review-
of-reviews supported the effectiveness claim of SMS-
interventions in for instance diabetes self-management
and weight loss but cost-effectiveness data was lacking
[99]. However, a recent study found dominant results of
SMS-interventions in the prevention of T2DM [100].
Limitations
Every health economic model is a simplification of the
reality. The current health economic evaluation is also
limited by the study’s multi-country perspective. The
accessibility of health and economic data differs across
countries. Clinical data can be extrapolated across coun-
tries with caution but economic data is a function of
country-specific characteristics [101]. Therefore, data
imputation was inevitable. We were able to mitigate this
limitation by consequently using Belgian data as starting
point for the imputation process. It needs to be empha-
sized that even though clinical data extrapolation across
countries is possible, this remains a limitation of the
health economic evaluation. We applied clinical data
extrapolation several times (e.g. Dutch CHD and stroke
mortality rates extrapolated to the Belgian context).
Furthermore, diaries and process evaluation questionnaires
were used to collect cost data collection. Although tem-
plates were available, it is not unthinkable that researchers
and participants might interpret questions differently.
Moreover, one disadvantage of questionnaires is the recall
bias, leading to less accurate input data. In addition, as
already stated by Pil et al. [10], measurements such as waist
circumference might be more valid predictors for T2DM
than BMI. Waist circumference was only measured in
adults in F4D. To keep the model manageable and to in-
crease its uniformity, we decided to use BMI as the pre-
dictor. The fact that we had to use intermediate endpoints
such as BMI, and we could not use measured hard end-
points such as T2DM prevalence is a major shortcoming
of the health economic evaluation. Finally, we extrapolated
the intervention effect on children to the adult age, which
increases the uncertainty of the analysis significantly. Cal-
culated endpoints are subject to the participants’ lifestyle as
teenager and young adult. Appropriate and extensive sensi-
tivity analysis will therefore be conducted.
Conclusion
The Feel4Diabetes-study aims to tackle T2DM by weight
status-related lifestyle modifications in populations at
risk. As policy makers cannot fund all interventions that
turn out to be effective, health economic evaluations
have the advantage to contribute to the optimal use of
the limited resources. The current paper describes the
methodology behind the cost-effectiveness assessment of
the Feel4Diabetes-study.
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